Ajanta Pharma Limited (BOM:532331)
2,607.30
-63.10 (-2.36%)
At close: Feb 21, 2025
Ajanta Pharma Revenue
Ajanta Pharma had revenue of 11.46B INR in the quarter ending December 31, 2024, with 3.71% growth. This brings the company's revenue in the last twelve months to 45.32B, up 12.27% year-over-year. In the fiscal year ending March 31, 2024, Ajanta Pharma had annual revenue of 42.09B with 12.45% growth.
Revenue (ttm)
45.32B
Revenue Growth
+12.27%
P/S Ratio
n/a
Revenue / Employee
5.61M
Employees
8,073
Market Cap
325.52B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
Mar 31, 2020 | 25.88B | 5.33B | 25.91% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
Tata Consultancy Services | 2,520.82B |
HDFC Bank | 2,702.59B |
Bharti Airtel | 1,627.08B |
ICICI Bank | 1,755.26B |
Infosys | 1,635.60B |
State Bank of India | 3,409.52B |
Hindustan Unilever | 626.61B |
Ajanta Pharma News
- 24 days ago - Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore - Business Upturn
- 2 months ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 4 months ago - Ajanta Pharma declares first interim dividend of ₹28 per share for FY25 - Business Upturn
- 4 months ago - Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore - Business Upturn